CASE REPORT

Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab

Guacimara Ortega Sanchez 1, Kathleen Jahn 2, Spasenija Savic 3, Alfred Zippelius 1,4 and Heinz Läubli 1,4,5*

Abstract

Background: The development of pulmonary immune-related adverse events (irAEs) in patients undergoing PD-(L)1 targeted checkpoint inhibitors are rare, but may be life-threatening. While many published articles and guidelines are focusing on the presentation and upfront treatment of pulmonary irAEs, the strategy in patients with late-onset pneumonia that are resistant to commonly used immunosuppressive drugs remains unclear.

Case presentation: Here, we report the successful treatment of a mycophenolate-resistant organizing pneumonia (OP) with infliximab in a patient with metastatic melanoma after PD-1 blockade. The patient received two years of PD-1 targeted immunotherapy when he developed multiple nodular lung lesions mimicking a metastatic progression. However, wedge resection of these lesions showed defined areas of OP, which responded well to corticosteroids. Upon tapering, new foci of OP developed which were resistant to high-dose steroids and mycophenolate treatment. The TNFα antagonist infliximab led to a rapid and durable regression of the inflammatory lesions.

Conclusion: This case describes a not well-studied situation, in which a mycophenolate-resistant PD-1 blocker-associated pneumonitis was successfully treated with a TNFα neutralizing antibody. The outcome of this case suggests that infliximab might be the preferable option compared to classical immunosuppressants in the case of steroid-resistant/−dependent late onset pulmonary irAEs.

Keywords: Immune checkpoint inhibitor, Cancer immunotherapy, Pneumonitis, Lung, Immune-related adverse event

Background

Blocking antibodies that target the immune checkpoint PD-(L)1 have led to durable remissions in various cancers including but not limited to melanoma, non-small cell lung cancer (NSCLC), bladder cancer and renal cell carcinoma [1–3]. Although PD-(L)1 targeted checkpoint inhibitors are most often well tolerated, 10–15% patients develop severe immune-related adverse events (irAEs) [4–8]. In addition, combination immunotherapies including PD-(L)1 and CTLA-4 targeted therapies have been approved and show an increased frequency of irAEs [9, 10]. Affections of the lung with irAEs are among the most dangerous and also most heterogeneous side effects of immune checkpoint inhibitors [7, 8, 11, 12]. A recent analysis of 915 patients showed a frequency of 5% (43 patients) in patients with PD-L(1) targeted monotherapy [12]. While guidelines for the treatment of pulmonary irAEs have been developed and help to manage these side effects ([4, 6, 8]; NCCN guidelines), the use of the optimal immunosuppressant in patients not or insufficiently responding to steroids remains less clear. Here, we describe a case with late-onset pulmonary irAE presenting as an organizing pneumonia (OP) that developed during PD-1 targeted checkpoint blockade with a corticosteroid dependency and resistance to classical immunosuppressants. We also summarize the current evidence for treatment strategies of steroid-resistant/−dependent pulmonary irAEs.

* Correspondence: heinz.laubli@unibas.ch
1Department of Internal Medicine, Division of Medical Oncology, University Hospital Basel, Basel, Switzerland
2Department of Biomedicine, Cancer Immunology Laboratory, University Hospital Basel, Basel, Switzerland
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Case presentation

We report a 75-year old man with stage IV BRAF V600E mutated malignant melanoma. On his initial \textsuperscript{18}fluoro-deoxy-glucose (FDG) positron emission tomography computed tomography (PET-CT) scan, he presented with multiple bilateral pulmonary nodules, bone and cutaneous lesions, peritoneal metastases and a lesion at the head of the pancreas (Fig. 1a and b). A palliative combination therapy with a BRAF- (dabrafenib 2x 150 mg) and MEK inhibitor (trametinib 2 mg) was started. Six weeks later a CT-scan revealed a partial remission of the lung, bone and cutaneous lesions but a progression of the lesion in the pancreas. A fine needle aspiration of the pancreatic lesion confirmed metastasis of the melanoma. This metastasis was irradiated and the combination targeted therapy continued. Eight months later, a progression with several new pulmonary lesions and peritoneal metastasis (Fig. 1) was observed and a second line therapy with the CTLA4 inhibitor ipilimumab (3 mg/kg) started. After 2 cycles, a disease progression (Fig. 1c) prompted a third line therapy with the PD-1 inhibitor pembrolizumab and radiotherapy of a myocardial metastasis. After the start of pembrolizumab, the condition of the patient rapidly improved and the patient achieved a good partial remission (Fig. 1). At 24 months under pembrolizumab a routine CT-scan showed multiple bilateral part solid lung lesions in the upper parts of the lung. At that stage, the patient reported NYHA II dyspnea. Endoscopically the tracheobronchial system was unremarkable. Bronchoalveolar lavage (BAL) demonstrated only a slight lymphocytosis of 13% lymphocytes without signs of pulmonary...
infection (negative microbiological cultures and PCR for viral pathogens). A transbronchial lung biopsy showed only normal lung morphology. Since it was unclear if the new lesions were metastases, we decided to surgically obtain a histological specimen. Wedge resection of several nodular lesions of the lung was therefore performed. Surprisingly, only one pulmonary lesion represented a melanoma metastasis with almost complete regressive necrosis as a sign of excellent response to treatment. The other lesions distant to the metastasis represented circumscribed areas of OP (Fig. 2). We found a strong CD3⁺ cell infiltration of the inflammatory lesion with predominantly CD4⁺ cells over CD8⁺ cells (Fig. 2e-g). Also, several FOXP3⁺ cells were found (Fig. 2h). Interestingly, clusters of PD-L1 positive macrophages were seen (Fig. 2i, SP-263 clone). A therapy with corticosteroids according to current guidelines for grade I-II pulmonary irAE was initiated with prednisone of 1 mg/kg and stopping of pembrolizumab. After a rapid regression of pulmonary lesions, the corticosteroid dose was tapered to 10 mg daily during a time period of 7 weeks. At this point, the patient presented with dyspnoea NYHA II and mainly thoracic pain. A CT revealed no lung embolism, but a progression of the bilateral part solid lung lesions corresponding to OP (Fig. 3a and b). With the OP relapse, a course of antibiotics and corticosteroids 50 mg daily was initiated with a rapid clinical and radiological improvement. A reduction of the corticosteroids by 10 mg every 4 weeks was recommended as performed for OP in routine pneumological practice. However, as soon as the doses of prednisone were lower than 20 mg daily a clinical and
radiological worsening was observed. For dose reduction/steroid sparing we decided to establish a combined immunosuppressive therapy consisting of mycophenolate mofetil (Cellcept) twice daily when the dose of prednisone 20 mg daily was reached again. After 4 weeks, the patients relapsed again with dyspnoea and new pulmonary lesions on the CT-scan (Fig. 3c). Because of the insufficient response to mycophenolate the TNFα-blocking agent infliximab was started. Initial dosing with 5 mg/kg was given for 3 doses and then a maintenance therapy was installed (100 mg). This led to a significant improvement after 4 months of therapy and corticosteroids could be completely stopped. The patient developed again dyspnoea at exertion, but a CT-scan showed no lung lesions or any direct cause for the dyspnoea (Fig. 3e). A cardiac stress test demonstrated some myocardial perfusion deficit and a coronary angiogram a high-grade stenosis of the left anterior descending (LAD) artery, which could be dilated and stented with a drug-eluting stent. After 6 months, infliximab was stopped and the patient is currently in an enduring very good partial remission for his melanoma (Fig. 3e).

Discussion

Immune checkpoint inhibitors are unequivocally one of the most important breakthroughs in cancer therapy in the past 10 years [2, 3, 13]. Immune system activation leads to rejection of cancer cells but may be harmful to healthy tissues [14]. Common irAEs include cutaneous, gastrointestinal, hepatic, pulmonary, and endocrine events [4–7]. Among them, immune-related pneumonitis has been reported to be a relatively uncommon but serious and potentially life-threatening irAE and has resulted in pneumonitis-related death in several Phase I trials [15–17]. Topalian et al. and colleagues reported several cases of pneumonitis with different findings ranging from isolated radiographic abnormalities to progressive, diffuse infiltrates associated with clinical symptoms which resulted in 3 deaths [15]. Pneumonitis—though a non-specific term—is defined as a non-infectious focal or diffuse reaction of the lung parenchyma, and includes different histological findings, e.g. sarcoid-like reaction, lymphocytic alveolitis, OP or even diffuse alveolar damage. Its incidence in studies with anti–PD-(L)1 mAbs has ranged from 0 to 10% [12, 18, 19]. Drug-related pneumonitis can also occur with chemotherapy (docetaxel, gemcitabine, bleomycin), targeted therapy (e.g. EGFR inhibitors, mTOR inhibitors), and radiation therapy. Its clinical characteristics are unspecific including non-productive cough, tachypnea and dyspnea on exertion and less often tachycardia, cyanosis, fatigue and occasional fever and chills. The presentation of pneumonitis is complicated with regard to diagnosis and unpredictable, and the disease tends to occur later than other irAEs [4–7, 12]. BAL can help to elucidate the underlying reaction of the lung parenchyma, for example in lymphocytic alveolitis. There are no criteria to differentiate drug-induced pneumonitis from other types of

![Fig. 3 Response of pulmonary inflammatory lesions to immune suppressive therapy.](image-url)
pneumonitis, nor are there criteria for assessing disease progression, which is important for determining treatment plans. Differential diagnoses have often to be considered including infections and also cancer progression. In particular in patients with primary pulmonary lesions or an underlying lung disorder, the diagnosis can be even more difficult. In this case, diagnosis was only made after thoracic surgery was performed. In unclear cases like the one presented, we always aim to obtain a histological diagnosis. Pulmonary irAEs – early and late onset – are graded based on the severity of its associated radiographic alterations and clinical symptoms. Grade 1 pneumonitis presents as radiographic alterations without respiratory discomfort, whereas grade 2 pneumonitis is characterized by low-intensity clinical symptoms. Grade 3–4 pneumonitis causes severe clinical symptoms, such as dyspnea, cough, and hypoxia [4–7]. Our patient presented initially with grade 2 pneumonitis.

The rate of grade 3/4 pneumonitis associated with nivolumab treatment was ≤ 1% in phase 3 non-small-cell lung cancer studies CheckMate-017, and CheckMate-057, with no deaths reported due to pneumonitis [18, 19]. Similar rates were seen in first line trials with nivolumab or pembrolizumab [20, 21]. Symptomatic pneumonitis is quite rare with ipilimumab monotherapy, and diffuse, grade 3/4 pulmonary toxicity is one of the irAEs that distinguishes anti-PD-(L)1 and anti-CTLA-4 immune checkpoint inhibitors [9, 22]. However, combination immunotherapy with ipilimumab and nivolumab for melanoma in the CheckMate-067 increased the risk for immune-related pneumonopathies [9]. In the CheckMate-214 trial of ipilimumab in combination with nivolumab for patients with metastatic RCC, one patient even died because of an immune-related pneumonitis [10]. Nishino and colleagues reviewed the frequency across different trials [23]. The odds in patients with melanoma and RCC that received combination therapy with ipilimumab and nivolumab was significantly increased (OR, 2.0, 95% CI 1.69–2.50, p < 0.001) [23]. Khunger and colleagues also performed a systematic review and meta-analysis of trials in the literature to evaluate the incidence pneumonitis with use of PD-(L)1 inhibitors in non-small cell lung cancer [24]. Nineteen trials (12 with PD-1 inhibitors [n = 3232] and 7 with PD-L1 inhibitors [n = 1806]) were identified. PD-1 inhibitors were found to have statistically significant higher incidence of any grade pneumonitis compared with PD-L1 inhibitors (3.6%; 95% CI, 2.4–4.9% vs 1.3%; 95% CI, 0.8–1.9%, p = .001). PD-1 inhibitors were also associated with higher incidence of grade 3 or 4 pneumonitis (1.1%; 95% CI, 0.6–1.7% vs 0.4%; 95% CI, 0–0.8%; p = .02). Treatment naïve patients had higher incidence of grade 1 through 4 pneumonitis compared with previously treated patients (4.3%; 95% CI, 2.4–6.3% vs 2.8%; 95% CI, 1.7–4%; p = .03). Naidoo et al. described clinical, radiologic, and pathologic features and management of 43 cases of pneumonitis as a result of anti–PD-1/PD-L1 mAbs from two separate institutions (Memorial Sloan Kettering Cancer Center: advanced solid cancers, 2009 to 2014, and Melanoma Institute of Australia: melanomas only) [12]. The overall incidence of pneumonitis was 5% (43 of 915 patients). Incidence was similar among patients with melanoma and NSCLC for monotherapy (3.6% vs 3.3%). Pneumonitis occurred irrespective of line of therapy in which immunotherapy was received (first line, 32%; second line, 40%; third line or more, 28%). All patients with grade 2 pneumonitis were treated initially with oral/intravenous corticosteroids (n = 14). Another overview of patterns showed also quite some heterogeneity [25]. Among 170 patients undergoing PD-(L)1 blocking therapy, 20 patients developed any grade of pneumonitis [25]. The most common radiographic pattern was consistent with OP similar as in our case.

Guidelines for the treatment of immune-related pneumonopathy that developed during checkpoint blockade in the case of steroid-refractory or steroid-dependent disease exist ([4–7]; NCCN guidelines). Several immunosuppressants are suggested including mycophenolate, or cyclophosphamide. Cases of pneumonitis with treatment strategies have been described in the literature. In one case, an immune-related pneumonitis caused by PD-1 inhibitor pembrolizumab in a patient with advanced esophageal carcinoma was described [26]. After six cycles of pembrolizumab (3 mg/kg every 3 weeks), the CT-scan showed diffuse ground glass opacity and consolidation in both lungs. Cellular interstitial pneumonitis was confirmed by pathological examination. Patient’s symptoms were alleviated after corticosteroid therapy. The pneumonitis recurred twice after stopping or tapering steroids quickly and could also be controlled by using steroids again (steroid dependency). No specific were given of alternative immunosuppressants [26]. Three cases with pneumonitis were reported in patients that have received radiotherapy prior to PD-1 blockade [27]. A series of 3 cases reported 1 patient who received nivolumab and ipilimumab sequentially, a second patient was treated with nivolumab and a third patient with ipilimumab before starting nivolumab [28]. The onset of pneumonitis occurred 7.4 to 24.3 months after the initiation of therapy. It is important to be aware that patients can develop this severe side effect even years after the initiation of PD-(L)1 blockade. CT imaging revealed findings seen in interstitial pneumonias. These conditions were CT-morphologically classified as acute interstitial pneumonia–acute respiratory distress syndrome (diffuse alveolar damage). Two patients were admitted to the intensive care unit and received intravenous antibiotic agents, glucocorticoids, and infliximab. Patient 1 required intubation, and his condition improved...
over the course of 10 weeks. Patient 2 died 4 weeks after the diagnosis of pneumonitis. Patient 3 had ground-glass opacities and reticular opacities indicative of nonspecific interstitial pneumonia. He discontinued nivolumab for 8 weeks and received oral glucocorticoids as an outpatient, and the pneumonitis resolved. In the cases reviewed by Naidoo et al., all patients with grade 3 or higher pneumonitis received oral/intravenous corticosteroids initially (n = 12), five (42%) of whom required additional immunosuppression (three with infliximab and two with both infliximab plus cyclophosphamide) [12]. For most patients who began oral corticosteroids, this was the maximum immunosuppression used (14 of 17 [82%]), with a median starting dose of prednisone of 50 mg (range, 20 to 80 mg) and median duration of corticosteroid treatment of 68 days (range, 20 to 154 days). In another cohort, 3 out 20 patients with pneumonitis were treated with infliximab [25]. In one patient, a combination treatment with cyclophosphamide and infliximab was needed. An overview of published cases with pneumonitis and infliximab treatment can be seen in Table 1. According to current evidence and guidelines (4, 6, 7; NCCN guidelines), we treated the patient initially with 1 mg/kg prednisone for grade 2 late onset immune-related pneumonitis. The patient became steroid-refractory and the immune suppression was extended by adding the classical immunosuppressant mycophenolate mofetil. It remains unclear which type of additional immunosuppressants is preferable in this situation. The late onset organizing pneumonia was not controlled and a further therapy with infliximab was started with rapidly improving pulmonary lesions. This outcome suggests that in the case of late onset pneumonitis during immune checkpoint blockade, TNFα inhibitors might be preferable compared to classical immunosuppressants, although more studies are needed to confirm this.

**Conclusion**

We report here the first case of steroid- and mycophenolate mofetil-resistant pneumonitis that presented as OP as a complication of PD-1-directed immunotherapy for melanoma. Immune-related pneumopathies are an uncommon but potentially serious toxicity that occurs in approximately 5% of patients who receive anti–PD-(L)1 mAbs. Most cases are mild and managed successfully with favorable outcomes. However, worsening pneumonitis may develop in a subset of patients despite additional immunosuppression, and they may suffer also from the immunosuppressive consequences of pneumonitis treatment. Infliximab can be used in steroid-refractory immune-related pneumopathies and might be preferable compared to other classical immunosuppressants. However, improvements in the treatment and understanding of the biology of immune-related pneumopathy are needed to optimize management.

**Table 1** Overview of published pneumonitis cases upon PD-(L)1 blockade that received a treatment with infliximab

| Publication | Number of Patients (%) | Patients with pneumonitis (%) | Treatment |
|-------------|------------------------|------------------------------|-----------|
| Chen et al. [26] | 1 | 1 | Corticosteroids |
| Lu et al. [27] | 3 | 3 | Corticosteroids |
| Nishino et al. [28] | 3 | 3 | Corticosteroids, 2 patients with infliximab |
| Naidoo et al. [12] | 915 | 43 (5%) | Corticosteroids, 5 patients with infliximab |
| 12 Grade 3–4 (1.3%) | 3 | 3 | Corticosteroids, 3 patients with infliximab |

**Abbreviations**

CT: Computed tomography; irAE: immune-related Adverse event; mAb: monoclonal antibody; MRI: Magnetic resonance imaging; PD-1: Programmed Death-1; PD-L1 or –L2: Programmed Death Ligand-1 or –2; TNFα: Tumor Necrosis Factor α

**Acknowledgements**

We thank the patient and her family for letting us present her case in this report.

**Authors’ contributions**

GOS, KJ, AZ and HL treated the patient and wrote the case report. SS analyzed the histological sections. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Ethics approval was obtained from the local ethical committee to analyze the tissue and blood samples. Written informed consent was obtained from the patient for the analysis of the samples and the tissue.

**Consent for publication**

A consent for publication was obtained from the patient. A copy of the written consent is available for review.

**Competing interests**

HL, and AZ received travel grants and consultant fees from Bristol-Myers Squibb (BMS) and Merck, Sharp and Dohme (MSD).

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1 Department of Internal Medicine, Division of Medical Oncology, University Hospital Basel, Basel, Switzerland. 2 Division of Pulmonary and Critical Care Medicine, University Hospital Basel, Basel, Switzerland. 3 Institute of Pathology, University Hospital Basel, Basel, Switzerland. 4 Department of Biomedical Research, University Hospital Basel, Basel, Switzerland. 5 Medical Oncology and Cancer Immunology, University Hospital Basel, Basel, Switzerland.
Received: 27 July 2018 Accepted: 16 August 2018
Published online: 03 September 2018

References

1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1380–5.
2. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–30.
3. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–61.
4. Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119–iv42.
5. Heinzerling L, Goldinger SM. A review of serious adverse effects under treatment with checkpoint inhibitors. Curr Opin Oncol. 2017;29(2):136–44.
6. Postow MA, Sidslow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68.
7. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559–74.
8. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME. Toxieties of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375–91.
9. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1435–46.
10. Motzer R, Nani N, DF MD, Arent Fronea O, Mellichar B, Chouein TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277–90.
11. Possick JD. Pulmonary toxicities from checkpoint immunotherapy for malignancy. Clin Chest Med. 2017;38(2):223–32.
12. Naidoo J, Wang X, Woo KM, Ilyetoz T, Halpenny D, Cunningham J. Pneumonitis in patients treated with anti-programmed Death-1/ programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709–17.
13. Howell M, Lee R, Bowyer S, Fusi A, Lorigan P. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. Lung Cancer. 2015;88(2):117–23.
14. June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med. 2017;23(5):540–7.
15. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.
16. Garon EB, Rizi V, Hui R, Lein M, Balmakudian AS, Eder JP. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.
17. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizi V, et al. Overall survival and long-term safety of Nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–12.
18. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(7):1627–39.
19. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung Cancer. N Engl J Med. 2015;373(2):123–35.
20. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Cosci T, Fulop A, et al. Pembrolizumab versus chemotherapy for PO-LI-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.
21. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line Nivolumab in stage IV or recurrent non-small-cell lung Cancer. N Engl J Med. 2017;376(25):2415–26.
22. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):123–34.
23. Nishino M, Gobbié-Hurder A, Hatabu H, Ramayia NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced Cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607–16.
24. Khunger M, Rakhit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung Cancer: a systematic review and meta-analysis of trials. Chest. 2017;152(2):271–81.
25. Nishino M, Ramayia NH, Awad MM, Sholl LM, Maatalla JA, Tabi M, et al. PD-1 inhibitor-related pneumonitis in advanced Cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051–60.
26. Chen YL, Zhao J, Jia R, Wang HY, Zheng J, Bai CQ, et al. Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review. Zhonghua Jie He Hu Xi Za Zhi. 2017;40(10):736–43.
27. Lu CS, Liu JH. Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: three case reports. Medicine (Baltimore). 2017;96(1):e5747.
28. Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramayia NH. Anti-PD-1-related pneumonitis during Cancer immunotherapy. N Engl J Med. 2015;373(3):288–90.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress. Learn more: biomedcentral.com/submissions